NCT04949828 (CisCP) is a clinical trial of CREON in Chronic Pancreatitis, sponsored by AbbVie.

Who is sponsoring NCT04949828?

NCT04949828 is sponsored by AbbVie.

What drugs are being tested in NCT04949828?

Interventions in NCT04949828: CREON.

What condition does NCT04949828 study?

NCT04949828 studies Chronic Pancreatitis.

Is NCT04949828 still recruiting?

NCT04949828 is currently completed. Last updated 28 March 2024.

Last reviewed 2024-03-28 · How we verify

NCT04949828: CisCP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

Completed Last updated 28 March 2024

What this trial tests

trial testing CREON in Chronic Pancreatitis in 63 participants. Completed in 29 February 2024.

Timeline

16 September 2021

Primary endpoint
29 February 2024

29 February 2024

Quick facts

Lead sponsor	AbbVie
Status	Completed
Study type	OBSERVATIONAL
Enrollment	63
Start date	16 September 2021
Primary completion	29 February 2024
Estimated completion	29 February 2024
Sites	6 locations across United States

Drugs / interventions tested

CREON (PROTEASE)) — full drug profile →

Conditions studied

Chronic Pancreatitis — all drugs for Chronic Pancreatitis →

Sponsor

AbbVie — full company profile →

Who can join

18 and older, any sex, with Chronic Pancreatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exocrine Pancreatic Insufficiency (EPI) is a condition where pancreatic enzyme quantity or activity is reduced below threshold needed for normal digestion. Symptoms include bloating, flatulence, diarrhea and steatorrhea. This is an observational study assessing for effect of CREON on symptoms of EPI in participants with EPI due to chronic pancreatitis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Management of chronic pancreatitis: recent advances and future prospects.
Han C, Lv YW, Hu LH. · · 2024 · cited 5× · PMID 38406795 · DOI 10.1177/17562848241234480
Pancrelipase Improves Symptoms of Exocrine Pancreatic Insufficiency and Health-Related Quality of Life in a Real-World Population of Patients with Chronic Pancreatitis.
Othman MO, Kort JJ, Ramsey ML, Gonda TA, et al · · 2026 · PMID 42126700 · DOI 10.1007/s10620-026-09952-0
Pancrelipase Treatment of Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis: Rationale and Methodology of a Real-World, Prospective, Observational Study.
Othman MO, Kort JJ, Gonda TA, Trikudanathan G, et al · · 2025 · PMID 40828651 · DOI 10.1097/mpa.0000000000002506

Verify or expand the search:

Other trials of CREON

Trials testing the same drug.

NCT05266963 — Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes · EARLY_PHASE1 · completed
NCT05069597 — Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pa · Phase 4 · completed
NCT04315311 — Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic F · Phase 4 · withdrawn
NCT01652157 — Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large I · terminated

Other recruiting trials for Chronic Pancreatitis

Currently open trials in the same condition.

NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT06655051 — Single Plastic Stent Vs. Fully Covered Self-Expanding Metal Stent on Benign Biliary Stricture Secondary to Chronic Pancr · NA · recruiting
NCT06937294 — Metformin in Post Chronic Pancreatitis Diabetes Mellitus · Phase 4 · recruiting
NCT07109180 — Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOT · NA · recruiting
NCT06925204 — Natural Course and Therapeutic Effect of Chronic Pancreatitis · recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04949828 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 28 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04949828.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing